Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma
- PMID: 15365064
- DOI: 10.1200/JCO.2004.01.012
Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma
Abstract
Purpose: Approximately 20% of sentinel node (SN) positive melanoma patients have additional non-SN (NSN) metastasis. The rationale for this study was to identify the factors associated with additional nodal disease, as a method to determine which patients may most benefit from completion lymph node dissection (CLND).
Patients and methods: During 1990 to 2002, 1,599 patients have undergone SN biopsy at our institute. 19.5% underwent CLND for tumor-positive SN. One hundred ninety-one of these patients had clinicopathologic information available for review. Univariate analyses used chi2 test, Wilcoxson rank sum test, and chi2 test for trend. Multivariate analyses used logistic regression and Wald test.
Results: Forty-six (24%) patients had tumor-positive NSN. Univariate analyses showed that primary thickness (Breslow and Clark), primary site, SN tumor size, and number of tumor-positive SNs were significantly associated with tumor-positive NSN. Multivariate analysis (167 patients), confirmed that Breslow and SN tumor size were independently predictive. Sex, histology, ulceration, mitotic index, and SN basin location were not predictive. Risk stratification by the number of prognostic factors present (Breslow > or = 3 mm and SN tumor size > or = 2 mm) showed that probability of finding tumor-positive NSN was 12.3% in the low-risk group (0 factors), 30.9% in the intermediate-risk group (1 factor), and 41.9% in the high-risk group (2 factors).
Conclusion: Thicker primary and larger SN tumor size are factors that correlate best with tumor-positive NSN. Although none of these factors are absolutely predictive of residual nodal disease, these factors must be strongly considered if the SN contains metastasis, as they provide enhanced risk assessment for NSN tumor-positivity.
Similar articles
-
Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma.J Am Coll Surg. 2005 Jul;201(1):37-47. doi: 10.1016/j.jamcollsurg.2005.03.029. J Am Coll Surg. 2005. PMID: 15978442
-
Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients.Eur J Surg Oncol. 2013 Feb;39(2):179-84. doi: 10.1016/j.ejso.2012.10.014. Epub 2012 Nov 6. Eur J Surg Oncol. 2013. PMID: 23137997
-
The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).Ann Surg Oncol. 2008 Aug;15(8):2223-34. doi: 10.1245/s10434-008-9965-3. Epub 2008 May 28. Ann Surg Oncol. 2008. PMID: 18506535
-
Prognostic heterogeneity after the excision of lymph node metastases in patients with cutaneous melanoma.Surg Oncol. 2011 Mar;20(1):26-34. doi: 10.1016/j.suronc.2009.09.004. Epub 2009 Nov 8. Surg Oncol. 2011. PMID: 19900803 Review.
-
Sentinel node mapping for melanoma: results of trials and current applications.Surg Oncol Clin N Am. 2007 Jan;16(1):35-54. doi: 10.1016/j.soc.2006.10.013. Surg Oncol Clin N Am. 2007. PMID: 17336235 Review.
Cited by
-
Surgical treatment of melanoma patients with early sentinel node involvement.Curr Treat Options Oncol. 2012 Sep;13(3):318-26. doi: 10.1007/s11864-012-0202-8. Curr Treat Options Oncol. 2012. PMID: 22810837 Review.
-
Evidence and implementation gaps in management of sentinel node-positive melanoma in the United States.Surgery. 2022 Jul;172(1):226-233. doi: 10.1016/j.surg.2021.12.025. Epub 2022 Feb 1. Surgery. 2022. PMID: 35120732 Free PMC article.
-
Treatment strategy for cutaneous malignant melanoma.Int J Clin Oncol. 2005 Oct;10(5):311-7. doi: 10.1007/s10147-005-0522-9. Int J Clin Oncol. 2005. PMID: 16247657 Review.
-
Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases.Ann Surg. 2003 Oct;238(4):538-49; discussion 549-50. doi: 10.1097/01.sla.0000086543.45557.cb. Ann Surg. 2003. PMID: 14530725 Free PMC article.
-
Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma.Cancer. 2009 Nov 1;115(21):5026-37. doi: 10.1002/cncr.24298. Cancer. 2009. PMID: 19658180 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical